# Article information:

Clinical experience: Outcomes of mesenchymal stem cell transplantation in five stroke patients - PMC  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892908/>

# Article summary:

1. Mesenchymal stem cell therapy is a viable option for stroke patients who miss the “thrombolytic treatment intervention window” or have hypoxic-ischemic encephalopathy.

2. Five stroke patients were treated with allogenic umbilical cord-mesenchymal stem cells (UC-MSCs) and followed up for 12 months.

3. Clinical outcomes showed significant improvement in NIH Stroke Scale/Scores (NIHSS) and Rivermead Assessment Scale (RMA).

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article provides an overview of the clinical experience of five stroke patients who were treated with allogenic umbilical cord-mesenchymal stem cells (UC-MSCs). The article is written by a team of researchers from various medical institutions, which adds to its trustworthiness and reliability. The authors provide evidence from recent studies in the literature to support their claims, which further adds to the credibility of the article.

However, there are some potential biases that should be noted. Firstly, the sample size used in this study is small, which may limit its generalizability. Secondly, the study does not explore any possible risks associated with UC-MSC transplantation, such as infection or rejection of the transplanted cells. Thirdly, there is no discussion on alternative treatments that could be used for stroke patients who miss the “thrombolytic treatment intervention window” or have hypoxic-ischemic encephalopathy. Finally, there is no mention of any counterarguments or opposing views regarding UC-MSC transplantation for stroke patients.

In conclusion, while this article provides an overview of mesenchymal stem cell therapy as a viable option for stroke patients who miss the “thrombolytic treatment intervention window” or have hypoxic-ischemic encephalopathy, it should be noted that there are some potential biases and missing points of consideration that should be taken into account when evaluating its trustworthiness and reliability.

# Topics for further research:

* Risks associated with UC-MSC transplantation
* Alternative treatments for stroke patients
* Hypoxic-ischemic encephalopathy treatment
* Thrombolytic treatment intervention window
* Pros and cons of UC-MSC transplantation
* Clinical trials of UC-MSC transplantation for stroke patients

# Report location:

<https://www.fullpicture.app/item/22c814af883264e5c778398c2844c6e3>